stockrow
Saturday 7 November 2026
Export PRME’s income statement to Excel — free account
Prime Medicine, Inc.
PRME Healthcare Biotechnology
Prime Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.6 million, up 55.3% from fiscal 2024.
- Revenue
- +3.50%
- EPS
- +41.5%
- Free cash flow
- +4.40%
Quarter to June 2026, against a year earlier
4.61
0.16
+3.60%
Follow PRME
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
160.56 | 152.77 | 111.44 | 148.77 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(15.93) | (14.43) | (13.86) | (25.38) | |
P/B ratio |
16.43 | 8.04 | 4.27 | 5.49 | |
Price to Tangible BV |
16.43 | 8.04 | 4.27 | 5.49 | |
EV/Sales |
137.22 | 119.19 | 73.08 | 113.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.58) | (3.07) | (2.08) | (6.20) | |
EV/FCF |
(3.56) | (3.03) | (2.03) | (5.87) | |
Quick Ratio |
3.00 | 3.73 | 4.74 | 6.09 | |
Current Ratio |
3.05 | 3.80 | 4.84 | 6.61 | |
Net Debt/EBITDA |
2.27 | 2.75 | 3.74 | 4.05 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.01 | 0.01 | 0.02 | |
Operating CF/Net income |
0.97 | 0.87 | 0.81 | 0.69 | |
Capex/Depreciation |
(0.03) | (0.15) | (0.27) | (0.19) | |
Research and Development Expense of Revenue |
2,894.02% | 3,984.23% | 4,141.89% | 3,591.02% | |
Selling, General and Administrative Expense of Revenue |
956.85% | 2,033.29% | 1,758.59% | 914.94% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
421.58% | 542.52% | 538.78% | 1,040.57% | |
Graham Net Nets |
(0.17) | (0.13) | (0.08) | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(29.92%) | (36.61%) | (40.18%) | (25.99%) | |
Free Cash Flow Yield |
(23.98%) | (25.76%) | (32.37%) | (12.94%) | |
Revenue per Share |
0.01 | 0.00 | 0.01 | 0.01 | |
Operating CF per Share |
(0.23) | (0.24) | (0.25) | (0.22) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.23) | (0.24) | (0.25) | (0.22) | |
Cash per Share |
0.54 | 0.77 | 1.19 | 1.33 | |
Shareholders Equity per Share |
0.22 | 0.43 | 0.81 | 1.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.22 | 0.43 | 0.81 | 1.01 | |
Free Cash Flow |
(41.09) | (42.92) | (37.55) | (35.29) | |
Working Capital |
65.11 | 101.60 | 143.85 | 196.39 | |
Capital Expenditures |
(0.05) | (0.21) | (0.29) | (0.25) | |
Net Current Asset Value |
(112.43) | (80.14) | (40.57) | 8.22 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.25 | 0.35 | 0.20 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
6.09 | 11.18 | 10.12 | 7.39 | |
Average Assets |
264.02 | 311.45 | 320.12 | 358.90 | |
Average Common Equity |
50.33 | 91.81 | 137.01 | 175.66 |
Columns are period end dates · fundamentals updated 25 Oct 2026